0000950170-23-068812.txt : 20231207 0000950170-23-068812.hdr.sgml : 20231207 20231207161505 ACCESSION NUMBER: 0000950170-23-068812 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231205 FILED AS OF DATE: 20231207 DATE AS OF CHANGE: 20231207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bryce Joanne CENTRAL INDEX KEY: 0001951845 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39438 FILM NUMBER: 231472546 MAIL ADDRESS: STREET 1: C/O DISC MEDICINE, INC. STREET 2: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Disc Medicine, Inc. CENTRAL INDEX KEY: 0001816736 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851613057 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (617) 674-9274 MAIL ADDRESS: STREET 1: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: Gemini Therapeutics, Inc. /DE DATE OF NAME CHANGE: 20210209 FORMER COMPANY: FORMER CONFORMED NAME: FS Development Corp. DATE OF NAME CHANGE: 20200702 4 1 ownership.xml 4 X0508 4 2023-12-05 0001816736 Disc Medicine, Inc. IRON 0001951845 Bryce Joanne C/O DISC MEDICINE, INC. 321 ARSENAL STREET, SUITE 101 WATERTOWN MA 02472 false true false false Chief Financial Officer true Common Stock 2023-12-05 4 M false 526 1.01 A 4286 D Common Stock 2023-12-05 4 M false 755 1.01 A 5041 D Common Stock 2023-12-05 4 S false 1148 55.2947 D 3893 D Common Stock 2023-12-05 4 S false 1293 56.5466 D 2600 D Common Stock 2023-12-05 4 S false 100 57.0600 D 2500 D Stock Option (Right to Buy) 1.01 2023-12-05 4 M false 526 0.00 D 2029-11-05 Common Stock 526 0 D Stock Option (Right to Buy) 1.01 2023-12-05 4 M false 755 0.00 D 2029-11-05 Common Stock 755 752 D The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.93 to $55.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.05 to $57.04, inclusive. The shares underlying this option are fully vested and exercisable as of the date hereof. The shares underlying this option vest in 16 equal quarterly installments following May 1, 2020, subject to the Reporting Person's continued service on each such vesting date. By: /s/ Rahul Khara, as Attorney-in-Fact 2023-12-07